Core Viewpoint - Shenzhen Jingwang Electronics Co., Ltd. has experienced significant stock price fluctuations, with a cumulative increase exceeding 20% over three consecutive trading days, prompting a warning for investors to exercise caution in their investment decisions [1][2]. Company Overview - The company specializes in the research, development, production, and sales of PCBs (Printed Circuit Boards), including multi-layer boards, thick copper boards, high-frequency and high-speed boards, metal-based circuit boards, double-sided/multi-layer flexible circuit boards, high-density flexible circuit boards, HDI boards, rigid-flex boards, special material PCBs, carrier boards, and packaging substrates [1]. - Its products are widely used in various sectors such as automotive, next-generation communication technology, data centers, AIoT, consumer electronics, industrial interconnect, medical devices, new energy, and satellite communication [1]. Stock Performance - The stock price of the company reached a new high on June 30, 2025, following a significant short-term increase, which has raised concerns about potential investment risks [1]. - The company's recent trading volume has significantly exceeded previous levels, indicating heightened market activity [3]. Shareholder Actions - The controlling shareholder, Jinghong Yongtai Investment Holdings Co., Ltd., along with other related parties, has announced a plan to reduce their holdings by a total of 29.49 million shares, which is up to 3% of the company's total share capital, through both centralized bidding and block trading methods [3][4]. - As of the announcement date, the reduction plan is currently in progress, with a portion of shares already sold in accordance with the disclosed plan [4]. Regulatory Compliance - The company has confirmed that there are no undisclosed matters that should be reported according to the regulations of the Shanghai Stock Exchange [5].

天风证券股份有限公司 关于博通集成电路（上海）股份有限公司 部分募投项目结项及部分募投项目变更、延期 的核查意见 天风证券股份有限公司（以下简称"天风证券"或"保荐机构"）作为博通 集成电路（上海）股份有限公司（以下简称"博通集成"或"公司" ）2020 年度 非公开发行股票的保荐机构，根据《上市公司募集资金监管规则》《上海证券交 易所股票上市规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等有关规定，对公司部分募投项目结项及部分募投项目变更、延期的事项进 行了审慎核查，具体核查情况如下： 一、募集资金基本情况 （一）2019 年首次公开发行股票募集资金情况及项目结项情况 经中国证券监督管理委员会"证监许可2019354 号" 《关于核准博通集成电 路（上海）股份有限公司首次公开发行股票的批复》核准，向社会公开发行人民 币普通股（A 股）股票 34,678,384.00 股，每股发行价格为人民币 18.63 元，募集 资金人民币 646,058,293.92 元，募集资金净额为 603,076,507.38 元。上述资金到 位情况业经立信会计师事务所（特殊普通合伙）验证，并出具信会师报字2 ...

| 投资者名称 | 变动前股数 | 变动前比例 | 变动后股数 | 变动后比例 | 权益变动方式 | | 权益变动的 | | --- | --- | --- | --- | --- | --- | --- | --- | | | (万股) | (%) | (万股) | (%) | | | 时间区间 | | 发生直接持股变动的主体: | | | | | | | | | 深圳市景鸿永 | | | | | 集中竞价 | ■ | | | 泰投资控股有 | 28.935.5322 | 30.95% | 28.652.5322 | 30.65% | 大宗交易 | 7 | 2025/6/30- | | | | | | | | | 2025/6/30 | | 限公司 | | | | | 其他:被动稀释 | | | | 智创投资有限 | | | | | 集中竞价 | | 2025/6/27- | | | 28.905.6408 | 30.92% | 28,228.9408 | 30.19% | 大宗交易 | 7 | | | 公司 | | | | | | | 2025/6/30 | | | | | | | 其他:被动稀释 | | ...

Key Takeaways TECH struck a deal with USP to distribute mAb and AAV standards, alongside its Maurice analytics platform. TECH aims to ease analytical challenges in mAb and gene therapy development through this partnership. TECH's tools enable efficient, integrated analysis of complex biologics from development to product release.Bio-Techne Corp. (TECH) has recently entered into a distribution agreement with the U.S. Pharmacopeia (“USP”) to sell USP monoclonal antibody (mAb) and recombinant adeno-associate ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is in a rapid growth phase, with a projected revenue of 503 million yuan for the first half of 2025, representing a year-on-year increase of 37%. The net profit attributable to the parent company is expected to reach 99 million yuan, with a year-on-year growth of approximately 267% [1][2] - The company benefits from increased customer demand, new customer acquisition, and the successful launch of new products, including AI chips and BLE6.0 chips, which have gained significant market traction [2][3] - The company has demonstrated significant scale effects, with net profit growth outpacing revenue growth due to higher sales of high-margin products and operational leverage [3] Summary by Sections Financial Performance - For the first half of 2025, the company expects a revenue of 503 million yuan, a 37% increase year-on-year, and a net profit of 99 million yuan, reflecting a 267% increase. Excluding stock payment expenses, the net profit is approximately 119 million yuan [1][2] - The net profit margin is projected to reach around 19.7%, significantly higher than the previous year's figures [3] Market Position and Product Development - The company holds a leading position in the low-power Bluetooth SoC chip market and is the largest domestic Zigbee chip supplier, maintaining a strong global presence [2] - New product launches, such as the edge AI chip and Matter chip, have entered mass production and are well-received in the market, contributing to revenue growth [2][3] Future Outlook - The company is expected to maintain rapid growth, with revenue forecasts for 2025 to 2027 set at 1.115 billion yuan, 1.466 billion yuan, and 1.857 billion yuan, respectively [4][10] - The net profit forecasts for the same period have been revised upwards, indicating strong growth potential [9]

WISeKey Shareholders Approved All Agenda Items of the 2025 Annual General Meeting Geneva, Switzerland, June 30, 2025 –WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its shareholders approved all items on the agenda of WISeKey’s 2025 Annual General Meeting held on June 27, 2025. Shareholders of WISeKey approved all proposals submitted by the Board of Directors, including the following: The Annual Repor ...

Core Viewpoint - Plus Therapeutics has initiated the ReSPECT-LM dose optimization trial for REYOBIQ™ to determine the optimal dosing schedule for treating leptomeningeal metastases, building on previous trial results and supported by a $17.6 million grant from CPRIT [1][7]. Trial Design and Objectives - The trial aims to optimize treatment dosing for maximum efficacy and safety, focusing on the safety and tolerability of multiple REYOBIQ doses administered via intraventricular catheter [2]. - Primary objectives include identifying the maximum tolerated dose and minimum effective dose for patients with LM from any primary solid tumor cancer [2]. Enrollment and Study Details - The trial will enroll up to 24 patients, evaluating REYOBIQ at a recommended Phase 2 dose of 44.1 mCi across three dosing intervals [4]. - Key cohorts include dosing intervals of 56 days, 28 days, and 14 days, with up to six patients per cohort [4]. Efficacy and Safety Data - Previous trials showed a clinical benefit rate of 76%, with 29% of patients achieving partial responses and 47% maintaining stable disease [5]. - No dose-limiting toxicities were observed in the first four cohorts, although one Grade 4 DLT occurred in each of Cohorts 5 and 6 [5]. Future Plans - The company plans to present data from the completed single-dose escalation trial at the SNO/ASCO CNS Metastases Conference in August 2025 and will request an End of Phase 1 Type B meeting with the FDA [6]. About Leptomeningeal Metastases - Leptomeningeal metastases occur in approximately 5% of patients with metastatic cancer, with median survival typically ranging from 2 to 6 months, highlighting the urgent need for effective treatment options [8]. About REYOBIQ™ - REYOBIQ™ is a novel injectable radiotherapy designed for targeted high-dose radiation in CNS tumors, with potential advantages over currently approved therapies [9]. Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for challenging CNS cancers, with a pipeline that includes treatments for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancer [10].

IRVINE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Lantronix Inc. (NASDAQ: LTRX) (the “Company”), a global leader in compute and connectivity IoT solutions enabling Edge AI intelligence, today announced that it has entered into a cooperation agreement with Lantronix stockholders Chain of Lakes Investment Fund LLC (“Chain of Lakes”), Haluk L. Bayraktar and Emre Aciksoz. Under the terms of the agreement, James (Jim) C. Auker will be appointed to the Lantronix Board of Directors (the “Board”) and will be nomina ...

文|恒心 来源|博望财经 | [编纂]的[编纂]數目 | .. | [编纂]股日股(視乎[编纂] | | --- | --- | --- | | 行使與否而定) | | | | [编纂]數目 | | [编纂]股H股(可予重新分配) | | [编纂]數目 | | 【编纂】股H股(可予重新分配及視乎 | | [编纂]行使與否而定) | | | | 最高 编纂] | | : 每股H股[编纂]港元,另加1.0%經紀佣金、 | | 0.0027%證監會交易徵費、0.00015% | | | | 會財局交易徴費及0.00565%聯交所交易費 | | | | (須於[編纂]時以港元繳足,多繳款項可予 | | | | 張賞) | | | | 面值 | : | 每股H股人民幣1.00元 | | 【编纂】 | .. | 【编纂】 | | 聯席保薦人、整體協調人、[編纂] | | | | 1 @ I Dollar | | 0 4 1 | 全球安卓端BIoT龙头商米科技要冲击港股IPO了。 代工模式虽降低重资产投入，却导致毛利率长期受制于上游供应链。2024年28.9%的毛利率虽较前两年有所回升，但仍显著低于具备自主生产能力的新大 ...

Meet The Iranian Immigrant Who Became A Biotech Billionaire https://t.co/n4Z7LPZR28 #SelfMadeWomen ...